Abstract
The rate of substance use, particularly cannabis, among patients with psychosis is high and much greater than in the general population. Persistent cannabis use by patients with an established psychotic disorder adversely affects prognosis and recovery. Little agreement has been reached on the reasons that sustain cannabis use in patients with psychosis although self-report studies have shown that patients appear to use cannabis largely for the same reasons as the general population i.e. to ‘get high’ or reduce negative states such as depression and boredom. The aim of this series is to explore 5 individual cases of patients with psychosis reporting cannabis use. Full clinical assessment for each patient as well as cannabis use history, reasons for use and implications for effective treatment are explored.
Keywords: Psychosis, schizophrenia, cannabis use, reasons for cannabis use, prognosis, recovery, general population, depression, boredom, cannabis use history.
Current Pharmaceutical Design
Title:Why do Psychotic Patients use Cannabis? Case Series
Volume: 18 Issue: 32
Author(s): Anna Kolliakou, Khalida Ismail and Zerrin Atakan
Affiliation:
Keywords: Psychosis, schizophrenia, cannabis use, reasons for cannabis use, prognosis, recovery, general population, depression, boredom, cannabis use history.
Abstract: The rate of substance use, particularly cannabis, among patients with psychosis is high and much greater than in the general population. Persistent cannabis use by patients with an established psychotic disorder adversely affects prognosis and recovery. Little agreement has been reached on the reasons that sustain cannabis use in patients with psychosis although self-report studies have shown that patients appear to use cannabis largely for the same reasons as the general population i.e. to ‘get high’ or reduce negative states such as depression and boredom. The aim of this series is to explore 5 individual cases of patients with psychosis reporting cannabis use. Full clinical assessment for each patient as well as cannabis use history, reasons for use and implications for effective treatment are explored.
Export Options
About this article
Cite this article as:
Kolliakou Anna, Ismail Khalida and Atakan Zerrin, Why do Psychotic Patients use Cannabis? Case Series, Current Pharmaceutical Design 2012; 18 (32) . https://dx.doi.org/10.2174/138161212802884807
DOI https://dx.doi.org/10.2174/138161212802884807 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Subset Selection and Docking of Human P2X7 Inhibitors
Current Computer-Aided Drug Design Patent Selections
Recent Patents on Cardiovascular Drug Discovery Editorial (Thematic Issue: The Changing Face of Metabolic Syndrome and its Components in the Light of Current Knowledge)
Current Vascular Pharmacology Meet Our Editorial Board Member:
Current Pharmaceutical Analysis Suicides and Suicide Attempts Among Psychiatric Hospital Inpatients in Iran
Current Psychiatry Research and Reviews A Concept of Homeostatic Inflammation Provided by Endogenous TLR4 Agonists that Function Before and After Danger Signal for Metastasis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Androgen Receptor in Human Health: A Potential Therapeutic Target
Current Drug Targets Pathophysiology and Prevention of Bronchopulmonary Dysplasia
Current Pediatric Reviews H3K4 Methylation Status and Lysine Specific Methyltransferase KMT2C Expression Correlate with Prognosis in Lung Adenocarcinoma
Current Molecular Pharmacology Spatio-Temporal Fluctuations of Neural Dynamics in Mild Cognitive Impairment and Alzheimer’s Disease
Current Alzheimer Research Overview of Experimental and Conventional Pharmacological Approaches in the Treatment of Sleep and Wake Disorders
Current Topics in Medicinal Chemistry Serum Albumin Concentration and Cognitive Impairment
Current Alzheimer Research Neurotrophins - From Pathophysiology to Treatment in Alzheimers Disease
Current Alzheimer Research Fibromyalgia: Mechanisms, Current Treatment and Animal Models
Current Pharmaceutical Biotechnology Editorial (Thematic Issue: Targeting Anti-Cancer Agents and Cancer Treatments)
Anti-Cancer Agents in Medicinal Chemistry Impact of Sex Hormone Metabolism on the Vascular Effects of Menopausal Hormone Therapy in Cardiovascular Disease
Current Drug Metabolism Selective Serotonin-norepinephrine Re-uptake Inhibition Limits Renovas-cular-hypertension Induced Cognitive Impairment, Endothelial Dysfunction, and Oxidative Stress Injury
Current Neurovascular Research Role of Protein Conformational Dynamics and DNA Integrity in Relevance to Neuronal Cell Death in Neurodegeneration
Current Alzheimer Research Artificial Hibernation by Phenothiazines: A Potential Neuroprotective Therapy Against Cerebral Inflammation in Stroke
Current Neurovascular Research Vortioxetine vs. Other Antidepressants in Patients with Major Depressive Episode With or Without Substance Use Disorder
Current Neuropharmacology